Cytek Biosciences financials
$5.76+0.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.1M | $44.1M | $62.1M | $52.3M | $45.6M | $41.5M | $57.5M | $51.5M | $46.6M | $44.9M | $58.2M | $48.0M |
| Gross profit | $28.3M | $21.3M | $32.9M | $27.6M | $23.9M | $20.2M | $33.7M | $29.0M | $25.4M | $23.0M | $33.0M | $27.2M |
| Gross margin | 58.9% | 48.2% | 52.9% | 52.7% | 52.3% | 48.6% | 58.5% | 56.3% | 54.6% | 51.3% | 56.8% | 56.6% |
| Operating income | -$11.4M | -$18.5M | -$5.6M | -$9.2M | -$10.6M | -$15.0M | $3.0M | -$4.2M | -$8.5M | -$10.7M | -$137.0K | -$6.4M |
| Net income | -$12.2M | -$18.9M | -$44.1M | -$5.5M | -$5.6M | -$11.4M | $9.6M | $941.0K | -$10.4M | -$6.2M | $5.5M | -$6.5M |
| Net margin | −25.3% | −42.7% | −70.9% | −10.5% | −12.2% | −27.5% | 16.8% | 1.8% | −22.4% | −13.8% | 9.4% | −13.4% |
| Diluted EPS | $-0.09 | $-0.15 | $-0.34 | $-0.04 | $-0.04 | $-0.09 | $0.08 | $0.01 | $-0.08 | $0.00 | $0.04 | $-0.05 |
| EBITDA | -$9.4M | -$16.6M | -$3.7M | -$7.3M | -$8.7M | -$13.1M | $4.8M | -$2.4M | -$6.7M | -$9.0M | -$137.0K | -$4.7M |
| Operating cash flow | $1.4M | -$2.7M | -$771.0K | -$3.9M | $108.0K | -$125.0K | $2.0M | $13.2M | $6.2M | $4.0M | $9.5M | -$4.2M |
| Free cash flow | -$850.0K | -$4.9M | -$1.8M | -$4.6M | -$1.5M | -$974.0K | $1.1M | $12.2M | $5.2M | $3.4M | $8.0M | -$5.6M |
| Diluted shares | 129.5M | 128.7M | 128.2M | 127.5M | 126.9M | 128.3M | 127.3M | 132.8M | 131.4M | 130.9M | 133.6M | 136.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $73.8M | $65.7M | $90.9M | $93.3M | $75.5M | $95.3M |
| Short-term investments | $188.2M | $196.6M | $170.7M | $168.5M | $186.6M | $170.3M |
| Total debt | $246.0K | $386.0K | $525.0K | $655.0K | $791.0K | $918.0K |
| Total assets | $446.9M | $449.1M | $461.5M | $494.9M | $493.3M | $482.6M |
| Total liabilities | $125.0M | $121.5M | $119.8M | $116.3M | $115.8M | $103.0M |
| Shareholders' equity | $322.0M | $327.6M | $341.7M | $378.6M | $377.6M | $379.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology